Kyverna Therapeutics (KYTX) Cash from Operations (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Cash from Operations data on file, last reported at 41597000.0 in Q1 2026.

• Quarterly Cash from Operations rose 7.36% year-over-year to 41597000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 150397000.0 (down 12.55% YoY) and the FY2025 annual result came in at 153700000.0, down 34.53% from the prior year.
• Cash from Operations slipped to 41597000.0 in Q1 2026, from 33515000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 11132000.0 in Q3 2023 to a low of 44900000.0 in Q1 2025.
• A 4-year average of 27842846.15 and a median of 27489000.0 in 2024 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations sank 146.94% — and 2025, when it rose 9.57%.
• Tracing KYTX's Cash from Operations over 4 years: stood at 18563000.0 in 2023, then sank by 99.65% to 37061000.0 in 2024, then advanced by 9.57% to 33515000.0 in 2025, then fell by 24.11% to 41597000.0 in 2026.
• The last three Cash from Operations figures came in at 41597000.0 (Q1 2026), 33515000.0 (Q4 2025), and 43321000.0 (Q3 2025), per Business Quant data.